ZA200103081B - Therapy for improving cognition. - Google Patents
Therapy for improving cognition. Download PDFInfo
- Publication number
- ZA200103081B ZA200103081B ZA200103081A ZA200103081A ZA200103081B ZA 200103081 B ZA200103081 B ZA 200103081B ZA 200103081 A ZA200103081 A ZA 200103081A ZA 200103081 A ZA200103081 A ZA 200103081A ZA 200103081 B ZA200103081 B ZA 200103081B
- Authority
- ZA
- South Africa
- Prior art keywords
- composition
- substance
- atypical antipsychotic
- acetylcholinesterase inhibitor
- active ingredient
- Prior art date
Links
- 230000019771 cognition Effects 0.000 title claims description 10
- 238000002560 therapeutic procedure Methods 0.000 title description 2
- 239000004480 active ingredient Substances 0.000 claims description 28
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 26
- 239000003693 atypical antipsychotic agent Substances 0.000 claims description 24
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 22
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims description 21
- 206010012289 Dementia Diseases 0.000 claims description 18
- 208000024827 Alzheimer disease Diseases 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 14
- 230000002411 adverse Effects 0.000 claims description 13
- 229960003980 galantamine Drugs 0.000 claims description 12
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims description 12
- 208000028017 Psychotic disease Diseases 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 229960001534 risperidone Drugs 0.000 claims description 11
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical group FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 9
- 229940127236 atypical antipsychotics Drugs 0.000 claims description 8
- 230000009286 beneficial effect Effects 0.000 claims description 8
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 230000001149 cognitive effect Effects 0.000 claims description 4
- 230000006866 deterioration Effects 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 230000002195 synergetic effect Effects 0.000 claims description 4
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical group FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 claims description 3
- 208000008454 Hyperhidrosis Diseases 0.000 claims description 3
- 206010028813 Nausea Diseases 0.000 claims description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 claims description 3
- 206010038743 Restlessness Diseases 0.000 claims description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 3
- 206010047700 Vomiting Diseases 0.000 claims description 3
- 229960003530 donepezil Drugs 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 229960003162 iloperidone Drugs 0.000 claims description 3
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 claims description 3
- 206010022437 insomnia Diseases 0.000 claims description 3
- 230000008693 nausea Effects 0.000 claims description 3
- 229960005017 olanzapine Drugs 0.000 claims description 3
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 229960004431 quetiapine Drugs 0.000 claims description 3
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims description 3
- 238000009097 single-agent therapy Methods 0.000 claims description 3
- 230000035900 sweating Effects 0.000 claims description 3
- 230000008673 vomiting Effects 0.000 claims description 3
- 229960000607 ziprasidone Drugs 0.000 claims description 3
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims description 3
- 208000027776 Extrapyramidal disease Diseases 0.000 claims description 2
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims description 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 2
- 229960004136 rivastigmine Drugs 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 13
- 239000003112 inhibitor Substances 0.000 claims 12
- 238000000034 method Methods 0.000 claims 11
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 150000007513 acids Chemical class 0.000 description 5
- -1 for example Chemical class 0.000 description 4
- 150000003839 salts Chemical group 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- ISYWECDDZWTKFF-UHFFFAOYSA-N nonadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCCC(O)=O ISYWECDDZWTKFF-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229960002024 galantamine hydrobromide Drugs 0.000 description 1
- QORVDGQLPPAFRS-XPSHAMGMSA-N galantamine hydrobromide Chemical compound Br.O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 QORVDGQLPPAFRS-XPSHAMGMSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98203454 | 1998-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200103081B true ZA200103081B (en) | 2002-07-12 |
Family
ID=8234219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200103081A ZA200103081B (en) | 1998-10-16 | 2001-04-12 | Therapy for improving cognition. |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1121131A2 (ko) |
| JP (1) | JP2002527469A (ko) |
| KR (1) | KR20010072878A (ko) |
| CN (1) | CN1367697A (ko) |
| AU (1) | AU6472799A (ko) |
| BG (1) | BG105302A (ko) |
| BR (1) | BR9914419A (ko) |
| CA (1) | CA2345767A1 (ko) |
| EE (1) | EE200100136A (ko) |
| HK (1) | HK1039745A1 (ko) |
| HR (1) | HRP20010262A2 (ko) |
| HU (1) | HUP0103781A3 (ko) |
| ID (1) | ID28441A (ko) |
| IL (1) | IL142588A0 (ko) |
| NO (1) | NO20011403L (ko) |
| PL (1) | PL348107A1 (ko) |
| SK (1) | SK4592001A3 (ko) |
| TR (1) | TR200101082T2 (ko) |
| WO (1) | WO2000023057A2 (ko) |
| ZA (1) | ZA200103081B (ko) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0102841D0 (en) * | 2001-02-05 | 2001-03-21 | Novartis Ag | Organic compounds |
| AU2006201188B2 (en) * | 2001-02-05 | 2007-11-15 | Novartis Ag | New use of iloperidone |
| CN1578664A (zh) | 2001-10-30 | 2005-02-09 | 诺瓦提斯公司 | 伊潘立酮和星状聚合物的贮库制剂 |
| GB0216416D0 (en) | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
| WO2004084905A2 (en) * | 2003-03-24 | 2004-10-07 | University Of Florida | Use of 5-ht2c receptor activity affecting compounds for treating idiopathic hyperhidrosis and associated conditions |
| TW200501962A (en) * | 2003-04-01 | 2005-01-16 | Novartis Ag | Use of carbamazepine derivatives for the treatment of agitation in dementia patients |
| CA2551486A1 (en) * | 2003-12-22 | 2006-06-22 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
| CA2552221A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Donepezil formulations |
| EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
| US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| AU2008220785B2 (en) | 2007-03-01 | 2013-02-21 | Vivoryon Therapeutics N.V. | New use of glutaminyl cyclase inhibitors |
| US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| MX2007008642A (es) * | 2007-07-16 | 2009-02-25 | World Trade Imp Export Wtie Ag | Composicion farmaceutica que comprende la combinacion de un agente derivado benzisoxazolico y un agente inhibidor reversible de la enzima colinesterasa, indicada para el control y tratamiento de trastornos psicoticos y demencias. |
| CA2789014C (en) | 2010-02-09 | 2019-01-15 | Michela Gallagher | Methods and compositions for improving cognitive function |
| US9181233B2 (en) | 2010-03-03 | 2015-11-10 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| DK2545047T3 (da) | 2010-03-10 | 2014-07-28 | Probiodrug Ag | Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5) |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
| JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
| CA2904767C (en) | 2013-03-15 | 2022-06-21 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
| US10806717B2 (en) | 2013-03-15 | 2020-10-20 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| CN107810002B (zh) | 2015-05-22 | 2021-01-05 | 艾吉因生物股份有限公司 | 左乙拉西坦的延时释放药物组合物 |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5336675A (en) * | 1991-05-14 | 1994-08-09 | Ernir Snorrason | Method of treating mania in humans |
| ATE183084T1 (de) * | 1991-05-14 | 1999-08-15 | Ernir Snorrason | Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren |
| CA2300148C (en) * | 1997-08-11 | 2009-06-23 | University Of South Florida | Nicotine antagonists for nicotine-responsive neuropsychiatric disorders |
| AU765603C (en) * | 1998-04-14 | 2004-08-05 | General Hospital Corporation, The | Methods for treating neuropsychiatric disorders |
-
1999
- 1999-10-12 KR KR1020017002286A patent/KR20010072878A/ko not_active Application Discontinuation
- 1999-10-12 PL PL99348107A patent/PL348107A1/xx unknown
- 1999-10-12 BR BR9914419-0A patent/BR9914419A/pt not_active IP Right Cessation
- 1999-10-12 WO PCT/EP1999/007804 patent/WO2000023057A2/en not_active Application Discontinuation
- 1999-10-12 EE EEP200100136A patent/EE200100136A/xx unknown
- 1999-10-12 SK SK459-2001A patent/SK4592001A3/sk unknown
- 1999-10-12 TR TR2001/01082T patent/TR200101082T2/xx unknown
- 1999-10-12 AU AU64727/99A patent/AU6472799A/en not_active Abandoned
- 1999-10-12 CN CN99812184A patent/CN1367697A/zh active Pending
- 1999-10-12 ID IDW20010828A patent/ID28441A/id unknown
- 1999-10-12 EP EP99952580A patent/EP1121131A2/en not_active Withdrawn
- 1999-10-12 CA CA002345767A patent/CA2345767A1/en not_active Abandoned
- 1999-10-12 HU HU0103781A patent/HUP0103781A3/hu unknown
- 1999-10-12 JP JP2000576832A patent/JP2002527469A/ja not_active Withdrawn
- 1999-10-12 IL IL14258899A patent/IL142588A0/xx unknown
-
2001
- 2001-03-01 BG BG105302A patent/BG105302A/xx unknown
- 2001-03-20 NO NO20011403A patent/NO20011403L/no not_active Application Discontinuation
- 2001-04-10 HR HR20010262A patent/HRP20010262A2/hr not_active Application Discontinuation
- 2001-04-12 ZA ZA200103081A patent/ZA200103081B/en unknown
-
2002
- 2002-01-10 HK HK02100158.6A patent/HK1039745A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL348107A1 (en) | 2002-05-06 |
| WO2000023057A3 (en) | 2000-07-27 |
| WO2000023057A2 (en) | 2000-04-27 |
| AU6472799A (en) | 2000-05-08 |
| EP1121131A2 (en) | 2001-08-08 |
| JP2002527469A (ja) | 2002-08-27 |
| IL142588A0 (en) | 2002-03-10 |
| BG105302A (en) | 2001-11-30 |
| SK4592001A3 (en) | 2001-12-03 |
| EE200100136A (et) | 2002-06-17 |
| HUP0103781A2 (hu) | 2002-03-28 |
| HK1039745A1 (zh) | 2002-05-10 |
| ID28441A (id) | 2001-05-24 |
| NO20011403D0 (no) | 2001-03-20 |
| KR20010072878A (ko) | 2001-07-31 |
| TR200101082T2 (tr) | 2001-09-21 |
| HRP20010262A2 (en) | 2002-06-30 |
| CA2345767A1 (en) | 2000-04-27 |
| NO20011403L (no) | 2001-03-20 |
| BR9914419A (pt) | 2001-06-26 |
| HUP0103781A3 (en) | 2003-09-29 |
| CN1367697A (zh) | 2002-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200103081B (en) | Therapy for improving cognition. | |
| DE60009697T2 (de) | Verwendung von 1-[4-(5-cyanoindol-3yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazin und dessen physiologisch akzeptablen salzen zur behandlung von bipolaren krankheiten und manie | |
| RU93004484A (ru) | Производные пиразола, способ их получения и содержащие их фармацевтические композиции | |
| KR20080014002A (ko) | 분산가능 정제 | |
| CZ284363B6 (cs) | Použití protikřečových činidel k přípravě léčiv určených k léčení Parkinsonovy choroby a Parkinsonových syndromů | |
| KR20120101456A (ko) | 중추 매개의 오심 및 구토를 치료하기 위한 조성물 및 방법 | |
| BG63933B1 (bg) | Инжекционна хинолонова лекарствена форма | |
| JPH08245417A (ja) | 鼻内投与のための薬学的非無機塩類液剤 | |
| SK8262001A3 (en) | Use of apomorphine in the manufacture of a medicament for the treatment of organic erectile dysfunction in males | |
| EP2862572A1 (en) | Prophylactic and/or therapeutic agent for mild cognitive impairment | |
| JP6836825B2 (ja) | 水不溶性またはわずかに水溶性の薬剤の水可溶性を改善するための方法 | |
| CN1317030C (zh) | 用中等剂量的lhrh拮抗剂治疗阿尔茨海默氏病 | |
| HK1079688A1 (en) | Statin product for enhancing cognitive maintenance | |
| JP5769912B2 (ja) | 認知障害を伴う疾患又は状態の予防又は治療用の組成物 | |
| JP2012500248A (ja) | 不安障害の治療 | |
| JP2022528481A (ja) | ピモジドとメトトレキサートの医薬組成物、及びその使用 | |
| JPH0678227B2 (ja) | ４−エチル−２−ヒドロキシイミノ−５−ニトロ−３−ヘキセンアミド含有製剤用の安定化剤、安定化方法及び安定化された製剤 | |
| EP0671908B1 (en) | Pharmaceutical compositions comprising 5-ht 1? receptor agonists and absorption enhancers | |
| KR20090024248A (ko) | Ｃｘｃｒ2의 선택적 길항제 또는 ｃｘｃｒ1과 ｃｘｃｒ2 둘다의 선택적 길항제의 약제학적 제형 및 조성물, 및 염증성 질환을 치료하기 위한 이의 사용방법 | |
| JP2004123558A (ja) | 片頭痛の予防、治療剤 | |
| CA1209047A (en) | Therapeutic composition containing piracetam analog | |
| NZ321370A (en) | Polymorphic forms of a growth hormone secretagogue | |
| JPH09227381A (ja) | 脳血栓における運動麻痺の改善剤 | |
| RU2001113270A (ru) | Лечение, направленное на улучшение познавательной способности | |
| CA2187651A1 (en) | Low dosage ranitidine compositions for the treatment of minor gastrointestinal disorders associated with excess acid secretion |